EN DE
Data-driven stock valuation

Terumo Corp ADR (TRUMY) fair value: what the stock is really worth

We calculate from audited financials what Terumo Corp ADR is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · US · Market cap $20.5B · ISIN US88156J1051

At a glance

TC Terumo Corp ADR logo Terumo Corp ADR TRUMY · US
Price$15.50
Fair Value$13.97
Upside−9.9%
Quality61/100

A solid business, currently priced close to our fair value of $13.97.

As of Sep 8, 2026, the fair value of Terumo Corp ADR is $13.97 per share against a price of $15.50, so the fair value sits 10% below the price. A model estimate from reported figures, not an analyst target.

✓Healthy Growth (revenue 5y +14.3 %/yr)
✓Solidly profitable · 12.0% net margin
✓Low debt · generates free cash flow
·1.33% dividend yield
✓Ranks above peers (10/15)
!Moderate moat 53/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 20 out of 100
!Weak on dividend: 27 out of 100
Evidence: Medium Range $10.48 to $17.46

Fair value as of: Sep 8, 2026

From 24 valuation models · updated today

Fair value updated Sep 8, 2026, revised from $13.54 to $13.97 (+3.2%) since Sep 1, 2026. Share price +7.3% over the past month.

Watch Terumo Corp ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • The price sits in the upper half of our model range, so the margin of safety is thin.
  • Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Price vs Fair Value (5 years)

$22.49 $12.10 Fair Value $13.97 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 8, 2026.

How to read this chart

60‑month range $12.10 – $22.49 · fair‑value band $10.48 – $17.46 · the $15.50 price screens above the $13.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 8, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Terumo Corp ADR (TRUMY) currently trades at $15.50, while our model-based Fair Value estimate is $13.97, implying the stock looks roughly 11.0% fairly valued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $28.59 per share, and 15 of the 24 models we run sit above the $15.50 price. Bear case: the Asset-Based group reads lowest at $4.55, and 9 of the 24 models stay below the price. Evidence for this calculation is medium.

Over the trailing twelve months, Terumo Corp ADR generated revenue of ¥1.1T at a net margin of 12.0%. Revenue grew 13.8% year over year. It earns a return on equity of 9.2%. Net debt stands at ¥99.7B. Fundamentals as of Sep 8, 2026

Scenario range: $10.48 (bear) to $17.46 (bull), the price of $15.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 17% below its 52-week high and 28% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at −10%, TRUMY screens cheaper than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
EPV $6.92 $7.94 $8.84 74
FCF DCF $11.88 $18.24 $38.51 73
Growth DCF $11.22 $21.50 $38.35 73
All 24 models by family
DCF Models
FCF DCF $11.88 $18.24 $38.51 73
Owner Earnings $11.16 $24.41 $52.21 68
5Y Revenue Exit $9.97 $16.81 $31.13 67
5Y EBITDA Exit $13.87 $24.70 $45.95 69
5Y P/E Exit $11.48 $24.64 $42.56 65
10Y Revenue Exit $10.35 $22.06 $29.59 64
10Y EBITDA Exit $13.54 $30.46 $60.35 62
10Y P/E Exit $11.80 $25.31 $47.50 58
Earnings-Based
Graham-Dodd $4.19 $29.19 $40.96 61
Lynch FV $15.08 $21.54 $28.00 59
PEG = 1.0 $15.08 $21.54 $28.00 55
EPV $6.92 $7.94 $8.84 74
Multiples
P/E Multiple $10.16 $13.54 $16.93 63
P/S Multiple $7.85 $10.46 $13.08 58
P/B Multiple $7.85 $10.46 $13.08 55
EV/EBIT $11.44 $15.00 $18.55 66
EV/EBITDA $14.10 $18.53 $22.97 67
EV/Revenue $8.39 $11.65 $14.91 54
Asset-Based
NCAV (Graham) $3.40 $4.55 $6.80 54
Growth DCF
Growth DCF $11.22 $21.50 $38.35 73
Rev-Margin DCF $10.94 $19.12 $36.22 67
Economic Profit
Residual Income $5.83 $6.37 $9.00 68
ROIC Compounder $7.09 $9.80 $12.51 70
Growth Earnings
Growth-Adj P/E $20.02 $28.59 $37.17 65

Widest divergence: Growth Earnings ($28.59) versus Asset-Based ($4.55). Highest evidence: EPV (74).

Notify me when TRUMY reaches fair value

Put TRUMY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 27.2
P/S ratio 3.27 P/E × margin
EPS (TTM) $0.5700 price ÷ EPS = P/E 27.2
Dividend yield 1.3% payout 36.2%
Net margin 12.0% FY2026
Return on equity 9.2% TTM
More key figures
Profitability
Return on assets (EBIT) 8.0% avg 5y
Operating margin 14.9% TTM
Growth
Revenue (TTM) ¥1.1T TTM
Revenue growth (YoY) +13.8% 3y avg +13.5%
EPS growth (YoY) +43.6%
Balance sheet & cash flow
Free cash flow ¥154B FY2026
Net debt ¥99.7B FY2026 · ≈ 0.6 yrs of FCF

Figures from reported company fundamentals · as of Sep 8, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 61/100

Of which business quality 61 · Market factors (momentum, volatility) 54

Profitability 45
Margins and returns on capital today
Quality Growth 47
Are margins and returns improving?
Cashflow 65
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 47
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 47
Price trend over the last 3–12 months (market factor)
52W Momentum 37
Distance to the 52-week high (market factor)
Net Issuance 87
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies.

Full company description

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The Terumo Organ Technologies segment provides organ preservation devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Shibuya, Japan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Terumo Corp ADR reported revenue of ¥1.2T in FY2026 versus ¥703B in FY2022, a compound +14.3%/yr. Reported net income was ¥144B in FY2026, compounding +12.9%/yr from FY2022.

Growth Quality 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2026)
¥1.2T
Latest YoY
+15.8%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.5%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.3%
Avg. revenue growth/yr (25Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.0%
Value creation/yr (5Y, in JPY) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+13.0%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+11.7%
Dividend yield1.3%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 11.7% vs 10Y 11.1%, steady
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16.0% (2021) → 16.3% (2026) · steady
Worst earnings drop22% (2012) · in JPY
Revenue +14.3%/yr
FY22 ¥703B
FY23 ¥820B
FY24 ¥922B
FY25 ¥1.0T
FY26 ¥1.2T
Net income +12.9%/yr
FY22 ¥88.8B
FY23 ¥89.3B
FY24 ¥106B
FY25 ¥117B
FY26 ¥144B
Character of growth · EPS growth decomposed (2015-2026) +11.0 % p.a.
Revenue per share +8.4 %

of which total revenue +8.4 % · buybacks/dilution +0.0 %

EBIT margin +0.6 %
Tax rate +1.5 %
Residual (interest, one-offs) +0.2 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

Watch TRUMY, get fair value alerts →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Terumo Corp ADR · Fair Value
$13.97 −11%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Terumo Corp ADR Fair Value". https://www.fairvalue-calculator.com/stock/TRUMY

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Medical Instruments & Supplies · 197 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 61 · Above median
Fair Value upside −13% · Above median
Profitability
Return on equity (TTM) 9% · Above median
Return on assets 6% · Above median
Net margin (TTM) 12% · Above median
Operating margin (TTM) 15% · Above median
Growth and dividend
Revenue growth 14% · Above median
Dividend yield (TTM) 1.3% · Below median
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 27.2× · Pricier than median
P/FCF 0.1× · Cheapest 25%
PEG 2.04× · Pricier than median

What the price implies (reverse DCF)

The inverse question: what free-cash-flow growth must Terumo Corp ADR deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.

Implied FCF growth, 10 years+6.3 % per year
Achieved revenue growth, 5 years+14.3 % p.a.
Sector median revenue growth+4.4 %
FCF yield on price4.40 %
Discount rate (WACC) in the models8.1 %

The price demands less growth than the company recently delivered: even a weaker business would justify the price. Ranking of the largest stocks →

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE20 · sector 0
FUTURE69 · sector 27
PAST37 · sector 26
HEALTH97 · sector 96
DIVIDEND27 · sector 30

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Sep 8, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $366.70 $150.04 −59%
EssilorLuxottica Société anonyme EL €160.35 €94.93 −41%
Medline Inc MDLN $36.59 $30.15 −18%
Becton, Dickinson and Company BDX $187.12 $100.46 −46%
Alcon Inc ALC $70.50 $39.78 −44%
ResMed Inc RMD A$33.19 A$26.23 −21%
West Pharmaceutical Services, Inc WST $339.97 $141.58 −58%
Sartorius Stedim Biotech S.A DIM €197.70 €48.88 −75%
Straumann Holding STMN CHF 97.38 CHF 47.31 −51%
Sartorius Aktiengesellschaft SRT3 €237.20 €63.30 −73%

Compare Terumo Corp ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Terumo Corp ADR (TRUMY) overvalued or undervalued?
As of Sep 8, 2026, our model estimates a fair value of $13.97 versus a price of $15.50, about −10% upside (fairly valued).
What is the fair value of TRUMY?
Our model-based fair value for Terumo Corp ADR is $13.97 (as of Sep 8, 2026), built from audited fundamentals. The current price: $15.50.
What is the quality score of TRUMY?
Terumo Corp ADR has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Terumo Corp ADR (TRUMY)?
Our model-based price target is the fair value of $13.97 (as of Sep 8, 2026) from 24 valuation models. Cautious scenario $10.48, optimistic scenario $17.46. It is a calculation from audited fundamentals, not an analyst target.
What is the Terumo Corp ADR stock forecast for 2026?
Our models put fair value at $13.97, about −10% upside versus a price of $15.50 (fairly valued). Cautious scenario $10.48, optimistic scenario $17.46. The calculation is refreshed regularly with new filings.
What is the revenue of Terumo Corp ADR (TRUMY)?
Terumo Corp ADR reported trailing-twelve-month revenue of about ¥1.1T (latest available figure, as of Sep 8, 2026).
What is the net profit margin of TRUMY?
The net profit margin of Terumo Corp ADR is about 12.0%, meaning it keeps roughly 12.0% of revenue as net income. Based on the latest reported figures.
Does Terumo Corp ADR pay a dividend?
Terumo Corp ADR currently shows a dividend yield of about 1.33% relative to its recent price (as of Sep 8, 2026).
What growth is priced into Terumo Corp ADR (TRUMY)?
For today's price to be fair in a discounted-cash-flow model, Terumo Corp ADR would have to grow free cash flow by +6.3 % per year for ten years (discount rate 8.1 %, then 2 % perpetual growth). Over the last 5 years revenue grew +14.3 % per year. As of Sep 8, 2026.
What discount rate (WACC) does the fair value of TRUMY use?
Our models discount Terumo Corp ADR at 8.1 %: a base by market capitalisation (large), damped by beta 0.21, country premium for USA. The same rate applies in all 26 models.
Free · no account needed

Watch Terumo Corp ADR in the live analysis

One click puts Terumo Corp ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.